PE Investor Carlyle which held 11% had exited Claris Lifesciences earlier in this year. Now, other FIIs have increased their stake in Claris...
Claris management has guided for 30 to 35% growth and it's a strong player in generic injectibles pharma business. Stock looks undervalued for...
Separate names with a comma.